SCHEMBL310138

SCHEMBL310138

CCc1cc(N2CCC(N3CCCCC3)CC2)ccc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.53
MAPT P10636 11/20 0.51
ALDH1A1 P00352 7/20 0.50
CYP1A2 P05177 4/20 0.50
CYP2C19 P33261 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
CYP2C9 P11712 3/20 0.50
L3MBTL3 Q96JM7 2/20 0.50
MAPK1 P28482 1/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 2/20 0.46
CYP3A4 P08684 1/20 0.46
TP53BP1 Q12888 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310337 0.92 MAPT (0.51) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL16284337 0.87 HPGD (0.68) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL18393128 0.82 LMNA (0.72) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL311491 0.82 ALDH1A1 (0.74) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL520231 0.81 ALDH1A1 (0.76) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL310306 0.80 L3MBTL3 (0.55) MAPTALDH1A1L3MBTL1L3MBTL3MAPK1
SCHEMBL309972 0.79 MAPT (0.58) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL21761929 0.79 LMNA (0.58) HPGDMAPTALDH1A1CYP1A2CYP2C19
SCHEMBL16284338 0.78 SIRT6 (0.68) MAPTALDH1A1L3MBTL1MAPK1
SCHEMBL15340797 0.77 MAPT (0.66) HPGDMAPTALDH1A1L3MBTL1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 HPGD 1913/4885MAPT 2367/4885ALDH1A1 3410/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 HPGD 1913/4885MAPT 2367/4885ALDH1A1 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.